Central nervous system relapse after combination therapy including polatuzumab vedotin in patients with diffuse large B-cell lymphoma

Yoshikazu Hori; Hiroki Hosoi; Toshiki Mushino; Yuka Okabe; Ayaka Sakaki; Kikuaki Yoshida; Yuichi Tochino; Yusuke Yamashita; Takashi Sonoki

doi:10.1016/j.lrr.2024.100467

Central nervous system relapse after combination therapy including polatuzumab vedotin in patients with diffuse large B-cell lymphoma

Leuk Res Rep. 2024 May 31:21:100467. doi: 10.1016/j.lrr.2024.100467. eCollection 2024.

Authors

Yoshikazu Hori¹, Hiroki Hosoi¹, Toshiki Mushino¹, Yuka Okabe¹, Ayaka Sakaki¹, Kikuaki Yoshida¹, Yuichi Tochino¹, Yusuke Yamashita¹, Takashi Sonoki¹

Affiliation

¹ Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.

Abstract

Preventing central nervous system (CNS) relapse is a major challenge in the treatment of diffuse large B-cell lymphoma (DLBCL). However, no previous studies have examined the efficacy of polatuzumab vedotin (PV)-containing regimens in preventing CNS relapse in patients with DLBCL. Here, we report two cases of CNS relapse after PV-containing chemotherapy for DLBCL. CNS relapse developed during combination therapy with PV, bendamustine, and rituximab (PV-BR) in one patient and six months after PV-BR in the other patient. PV-containing chemotherapy may be ineffective as a prophylaxis against CNS relapse; therefore, additional strategies for preventing CNS relapse in DLBCL patients are required.

Keywords: Central nervous system relapse; Diffuse large B-cell lymphoma; Polatuzumab vedotin.

Publication types

Case Reports